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Age Primary Adjuvant RT region 
No of 
positive 
nodes 
ECE Site of recurrence 
Time to 
recurrence 
post RT 
Mortality 
post 
recurrence 
64 Neck Neck 6/61 No - - - 
57 Unknown Neck 1/29 Yes - - - 
81 Cheek Neck 2/31 Yes Distant 4 months RIP at 4 months 
43 Leg Groin 9/25 No - - - 
41 Back Axilla 3/16 No - - - 
19 Neck Neck 1/35 Yes Distant 1 month Alive at 25months 
79 Eyelid Neck 1/58 Yes Local + Distant 3.5 months 
Alive at  
22months 
69 Auricular Neck 4/50 Yes - - - 
68 Unknown Neck 1/64 Yes - - - 
65 Cheek Neck 1/24 No - - - 
75 Unknown Neck 4/45 Yes Distant 4 months RIP at 1 month 
73 Neck Neck 0 No - - - 
62 Leg Groin 5/10 No - - - 
70 Leg Groin 13/33 No - - - 
57 Foot Groin 3/8 Yes Local + Distant 
0 months + 
2.8 months 
RIP at 
10months 
80 Cheek Neck 38/42 Yes Distant 1 month RIP at 7months 
48 Unknown Axilla 13/33 Yes - - - 
57 Hand Axilla 13/33 Yes Distant 2 months Alive at 8months 
63 Leg Groin 2/25 Yes - - - 
37 Leg Groin 1/9 Yes - - - 
 
Conclusion: Radiotherapy was well tolerated and effective as 
no patient developed lymph node field relapse. However 
patients are at risk of early local and distant relapse, 
especially those with extranodal extension. Consideration 
should be given to the use of routine PET CT for high risk 
patients.  
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Purpose or Objective: Surgery is the cornerstone in the 
management of sarcomas. The aim of this study was to 
evaluate intensity-modulated radiotherapy (RT) with 
tomotherapy followed by surgery in terms of acute gastro-
intestinal (GI) toxicities, especially regarding the high-level 
of prescribed dose (54 Gy/30 fractions/6weeks). 
 
Material and Methods: From April 2009 to September 2013, 
48 patients were included in a prospective multicenter study. 
Feasibility of tomotherapy, acute toxicities and local control 
at 3 years were the principal and secondary objectives. 
Inclusion criteria were operable, biopsy-proven, 
retroperitoneal liposarcoma. Patients with non-operable 
tumors validated after multi-disciplinary team evaluation, 
other histology or metastatic disease were excluded.Clinical 
Target Volume (CTV) and mains organs at risk (contralateral 
kidney, duodenum, bowel bag) were systematically 
delineated with the surgeon. Dose constraints to the bowel 
bag were defined as V45 Gy<33% and V30 Gy<50%. Surgery 
was planned 4 to 8 weeks after RT. Clinical visits were 
performed weekly during RT, before surgery, and 2 and 6 
months after surgery. Toxicity was recorded according to 
CTCAE V4.0 scale. 
 
Results: For acute GI toxicity, 46/48 patients were 
evaluable. All patients completed the radio surgical schedule 
without dose reduction. Mean age was 62 years (36-82). All 
patients were OMS≤2 except one (OMS=3). Mean CTV was 
2954 cc (920-4989. Mean small bowel and duodenal volumes 
were 2725 (1355-4090) and 73 cc (33-113), respectively. 
Monobloc exerese was systematically achieved and all 
patients underwent homolateral nephrectomy. Twenty-nine 
patients underwent bowel resection, including large bowel 
(28/29), small bowel(4/29) and duodenum (1/29). Mean 
weight loss during RT was 5,4 kg (about 8% of mean body 
weight) and 8,9 kg at the first visit after surgery. At 2 
months, grade 3 toxicities included duodenal stenosis (1/46), 
intestinal fistula (1/46) and enterocolitis (1/46) and grade 4 
toxicity included GI fistula (1/46). At 6 months, no GI 
toxicities were observed. Three patients died within 6 
months after surgery, 2 of which were related to treatment: 
one respiratory disorder 6 days after surgery and 1 duodenal 
perforation with necrosis and infection 4 months after 
surgery. 
 
Conclusion: For patients with retroperitoneal liposarcoma, 
preoperative 54 Gy RT appears feasible. Due to the low rate 
of severe complications, no statistic correlations with dose in 
digestive structure were performed. 
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Purpose or Objective: The standard treatment of high grade 
soft tissue sarcoma (STS) is surgery followed by adjuvant 
radiotherapy (RT); chemotherapy (CT) can be an option in 
selected patients due to reported benefit in terms of disease 
free survival. The association of RT with CT might increase 
tissue reactions with the consequent risk of unplanned 
treatment interruptions resulting in an increased risk of 
treatment failure. This retrospective study analyze the safety 
and feasibility, respectively in terms of additional toxicity 
and compliance, of concurrent chemoradiotherapy (CTRT) in 
adjuvant treatment of STS.  
 
Material and Methods: Data of 84 STS patients treated with 
surgery and adjuvant RT from June 1994 to November 2014 at 
the University of Florence, were retrospectively collected. 
Anthracycline-based CT was performed in high risk patients. 
Acute and late local toxicity of RT treatment were assessed 
respectively by Common Terminology Criteria for Adverse 
Events (CTCAE) 4.0 and RTOG/EORTC criteria for the Late 
Radiation Toxicity. CT-related hematological Toxicity was 
assessed by CTCAE 4.0. 
 
Results: Twenty-four (28.6%) patients received CTRT. Mean 
follow-up was 5.6 years (range 0.4-18.8). At the time of our 
analysis 8 (9,5%) patients had a local relapse, 17 (19.8%) 
developed distant metastases, and 14 (16.7%) died of 
metastatic disease. Local Recurrence Free Survival (LRFS), 
Distant Relapse Free Survival (DRFS) and Overall Survival (OS) 
were respectively 83.4%, 70% and 69.5%. Grade ≥3 leucopenia 
occurred in 6 CTRT patients, resulting in early interruption of 
the CT treatment in 3 cases. Skin acute toxicity was 
developed in 59 (70,2%) of patients ; G3 skin toxicity 
occurred in 19 (22.6%) cases and determined treatment 
interruption in 15 (17.9%) patients with a mean treatment 
